Uncomplicated Urinary Tract Infection Treatment Market Report 2024

The uncomplicated urinary tract infection treatment market size has grown rapidly in recent years. It will grow from $5.55 billion in 2023 to $6.12 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to several factors, increasing prevalence of urinary tract infections (UTIs), growing awareness and improved diagnosis, an aging population, improvements in healthcare policies and insurance coverage, and increasing government initiatives aimed at healthcare improvement.

The uncomplicated urinary tract infection treatment market size is expected to see rapid growth in the next few years. It will grow to $9.16 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to several factors, rising awareness campaigns about urinary tract infections (UTIs), increasing access to healthcare services, expansion of healthcare infrastructure, growing research funding in the field, and a favorable pharmaceutical marketing and regulatory environment. Major trends expected in this period include advancements in rapid diagnostic tests for UTIs, innovation in drug delivery systems for treatment, increased demand for home diagnostic kits, development of smartphone apps for UTI management, and greater adoption of digital health solutions in UTI diagnosis and treatment.

The uncomplicated urinary tract infection treatment market is set to grow due to the increasing incidence of hospital-acquired infections. These infections are acquired by patients during their hospital stays, often due to antibiotic-resistant bacteria, inadequate infection control measures, prolonged hospitalization, and compromised immune systems. The rise in hospital-acquired infections highlights the urgent need for effective strategies to treat urinary tract infections within healthcare settings, driving innovation and investment in this field. For example, according to the Australian Institute of Health and Welfare's June 2024 report, there were 1,668 cases of staphylococcus aureus bloodstream infections (SABSI) reported during 22.5 million patient care days in public hospitals. This resulted in a rate of 0.74 SABSI cases per 10,000 patient days, underscoring the impact of hospital-acquired infections on healthcare facilities.

Key players in the uncomplicated urinary tract infection treatment market are focusing on developing innovative products, such as parenteral carbapenem antibacterial agents, to improve treatment outcomes and combat antibiotic resistance. These broad-spectrum antibiotics are administered via injection and are effective against severe or resistant bacterial infections. For instance, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company, introduced BIAPENEM in September 2021. BIAPENEM is a parenteral carbapenem antibacterial agent used to treat intra-abdominal, lower respiratory, or urinary tract infections, offering a robust solution against a range of bacterial pathogens.

In July 2021, Pharmavite, a US-based company specializing in vitamins and supplements, acquired Uqora Inc., enhancing its portfolio in women's health solutions. Uqora Inc. is known for its non-prescription dietary supplements designed to support urinary tract health and manage urinary tract infection symptoms, aligning with Pharmavite's commitment to comprehensive healthcare solutions for women.

Major companies operating in the uncomplicated urinary tract infection treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Almirall S.A, Iterum Therapeutics PLC, Inmunotek S.L., Fimbrion Therapeutics Inc., Utility Therapeutics Ltd.

North America was the largest region in the uncomplicated urinary tract infection treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uncomplicated urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the uncomplicated urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Uncomplicated urinary tract infection (UTI) treatment involves diagnosing and managing infections that affect healthy individuals with normal urinary tracts, typically confined to the bladder and not involving structural or functional abnormalities. The primary objectives of treatment include eradicating the infection, alleviating symptoms, and preventing potential complications.

The main drug classes used in uncomplicated UTI treatment include gepotidacin, probenecid, sulfonamides, tetracyclines, and nitrofurans. Gepotidacin is an investigational antibiotic from the triazaacenaphthylene class, effective against both gram-positive and gram-negative pathogens. These infections can originate from sources such as hospital-acquired and community-acquired UTIs, affecting both males and females. Distribution channels for these treatments include hospital pharmacies, gynecology and urology clinics, retail pharmacies, and online drugstores.

The uncomplicated urinary tract infection treatment market research report is one of a series of new reports that provides uncomplicated urinary tract infection treatment market statistics, including the uncomplicated urinary tract infection treatment industry's global market size, regional shares, competitors with uncomplicated urinary tract infection treatment market share, detailed uncomplicated urinary tract infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the uncomplicated urinary tract infection treatment industry. This uncomplicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The uncomplicated urinary tract infection treatment market consists of sales of ciprofloxacin, levofloxacin, and ceftriaxonea. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.